Skip to main content

Understanding Viral Vector COVID-19 Vaccines

 

What You Need to Know

  • Viral vector vaccines use a modified version of a different virus (the vector) to deliver important instructions to our cells.
  • The benefit of viral vector vaccines, like all vaccines, is those vaccinated gain protection without ever having to risk the serious consequences of getting sick with COVID-19.

Viral vector vaccines are among the COVID-19 vaccines authorized for use in the United States.

How They Work

COVID-19 vaccines

Viral vector vaccines use a modified version of a different virus (the vector) to deliver important instructions to our cells.

  1. First, the vector (not the virus that causes COVID-19, but a different, harmless virus) will enter a cell in our body and then use the cell’s machinery to produce a harmless piece of the virus that causes COVID-19. This piece is known as a spike protein and it is only found on the surface of the virus that causes COVID-19.
  2. Next, the cell displays the spike protein on its surface, and our immune system recognizes it doesn’t belong there. This triggers our immune system to begin producing antibodies and activating other immune cells to fight off what it thinks is an infection.
  3. At the end of the process, our bodies have learned how to protect us against future infection with the virus that causes COVID-19. The benefit is that we get this protection from a vaccine, without ever having to risk the serious consequences of getting sick with COVID-19. Any temporary discomfort experienced after getting the vaccine is a natural part of the process and an indication that the vaccine is working.
Facts about COVID-19 Viral Vector Vaccines

They cannot give someone COVID-19 or other infections.

  • Viral vectors cannot cause infection with COVID-19 or with the virus used as the vaccine vector.

 They do not affect or interact with our DNA in any way.

  • The genetic material delivered by the viral vector does not integrate into a person’s DNA.

How They Are Being Rigorously Studied for Safety

Viral vector vaccines are safe and effective.

Viral vector vaccines for COVID-19 are being held to the same rigorous safety and effectiveness standardsexternal iconas all other types of vaccines in the United States. The only COVID-19 vaccines the U.S. Food and Drug Administration (FDA) will make available for use in the United States (by approval or emergency use authorization) are those that meet these standards.

How They Have Been Used during Recent Disease Outbreaks

Scientists began creating viral vectors in the 1970s. Besides being used in vaccines, viral vectors have also been studied for gene therapy, to treat cancer, and for molecular biology research. For decades, hundreds of scientific studies of viral vector vaccines have been done and published around the world. Some vaccines recently used for Ebola outbreaks have used viral vector technology, and a number of studies have focused on viral vector vaccines against other infectious diseases such as Zika, flu, and HIV.

source: www.cdc.gov

Comments

Popular posts from this blog

#COVID-19 #Vaccines and #Vaccination

  Key Points Available evidence suggests the currently authorized mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) provide protection against a variety of strains, including B.1.1.7 (originally identified in the United Kingdom) and B.1.351 (originally identified in South Africa). Other vaccines show reduced efficacy against B.1.351 but may still protect against severe disease. Continued monitoring of vaccine effectiveness against variants is needed. A growing body of evidence indicates that people fully vaccinated with an mRNA vaccine (Pfizer-BioNTech and Moderna) are less likely to have asymptomatic infection or to transmit SARS-CoV-2 to others. Studies are underway to learn more about the benefits of Johnson & Johnson/Janssen vaccine. However, the risk for SARS-CoV-2 infection in fully vaccinated people cannot be completely eliminated as long as there is continued community transmission of the virus. At this time, there are limited data on vaccine effectiveness in people who

Frequently Asked Questions about #COVID-19 #Vaccination

If I have already had COVID-19 and recovered, do I still need to get vaccinated with a COVID-19 vaccine? Yes, you should be vaccinated regardless of whether you already had COVID-19. That’s because experts do not yet know how long you are protected from getting sick again after recovering from COVID-19. Even if you have already recovered from COVID-19, it is possible—although rare—that you could be infected with the virus that causes COVID-19 again. Studies have shown that vaccination provides a strong boost in protection in people who have recovered from COVID-19. Learn more about why getting vaccinated is a safer way to build protection than getting infected. If you were treated for COVID-19 with monoclonal antibodies or convalescent plasma, you should wait 90 days before getting a COVID-19 vaccine. Talk to your doctor if you are unsure what treatments you received or if you have more questions about getting a COVID-19 vaccine. If you or your child has a history of multisystem inflam

COVID 19 - Delta and Delta Plus Variant

SARS-CoV-2 Delta variant, also known as lineage B.1.617.2, is a variant of lineage B.1.617 of SARS-CoV-2, the virus that causes COVID-19. It was first detected in India in late 2020. The World Health Organization (WHO) named it the Delta variant on 31 May 2021. It has mutations in the gene encoding the SARS-CoV-2 spike protein causing the substitutions T478K, P681R and L452R, which are known to affect the transmissibility of the virus as well as whether it can be neutralised by antibodies for previously circulating variants of the COVID-19 virus. Public Health England (PHE) in May 2021 observed secondary attack rates to be 51–67% higher than the alpha variant. On 7 May 2021, PHE changed their classification of lineage B.1.617.2 from a variant under investigation (VUI) to a variant of concern (VOC) based on an assessment of transmissibility being at least equivalent to B.1.1.7 (Alpha variant); the UK's SAGE subsequently estimated a "realistic" possibility of being 50% mor